<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">WARM, MATHIAS</style></author><author><style face="normal" font="default" size="100%">KATES, RONALD</style></author><author><style face="normal" font="default" size="100%">MALLMANN, PETER</style></author><author><style face="normal" font="default" size="100%">DICK, MICHÈLLE</style></author><author><style face="normal" font="default" size="100%">NAWROTH, FRANK</style></author><author><style face="normal" font="default" size="100%">HARBECK, NADIA</style></author><author><style face="normal" font="default" size="100%">PAEPKE, STEFAN</style></author><author><style face="normal" font="default" size="100%">THOMAS, ANKE</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of Tumor Biological Factors on Response to Pre-operative Epirubicin and Paclitaxel Chemotherapy in Primary Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1031-1038</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The objective of this study was to determine the predictive impact of several established tumor biological factors (progesterone receptor, estrogene receptor, HER2/neu, and Ki-67) on response to pre-operative combination chemotherapy with epirubicin and paclitaxel in a representative group of primary breast cancer patients. Patients and Methods: Thirty-eight primary breast cancer patients (metastasis-negative) received pre-operative chemotherapy with epirubicin and paclitaxel. The response characteristics analyzed included pathological complete response and partial remission determined by 3D ultrasound, as well as down-staging and breast conserving surgery. Results: Pathologically complete response occurred in six patients. Overexpression of HER2/neu, low (negative) hormone receptors and high Ki-67 were all significant positive predictive factors for response to pre-operative chemotherapy. Conclusion: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>